* Ginkgo Bioworks Holdings Inc is expected to show a fall in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
* The Boston Massachusetts-based company is expected to report a 18.8% decrease in revenue to $45 million from $55.43 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Ginkgo Bioworks Holdings Inc is for a loss of $2.84 per share.
* The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 4 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is 10.00, above its last closing price of $8.49.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -3.20 -3.12 -2.80 Beat 10.3
Jan. 1 2024 -3.36 -3.33 -3.20 Beat 4
Dec. 31 2023 -4.17 -3.87 -4.40 Missed -13.8
Sep. 30 2023 -3.34 -3.43 -6.40 Missed -86.7
Jun. -2.99 -3.37 -3.60 Missed -6.8
30 2023
Jan. 1 0001 -3.44 -3.60 -4.40 Missed -22.2
Dec. 31 2022 -8.52 -8.34 -3.60 Beat 56.8
Sep. 30 2022 -11.93 -11.84 -16.40 Missed -38.5
This summary was machine generated November 8 at 23:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments